problems in modern medicine, is responsible for approximately 71 million infections
worldwide. The global disease burden of children with HCV infection aged 0-18 years
old is estimated to be 0.13%, corresponding to 3.26 million children.
In 2018, the prevalence of Hchildren with HCV infection in the United States and
Europe was estimated to be 0.05%-0.36%.
To read this article in full you will need to make a payment
Global prevalence of hepatitis C virus in children in 2018: a modelling study.
Lancet Gastroenterol Hepatol. 2020; 5: 374-392
Burden of pediatric hepatitis C.
World J Gastroenterol. 2013; 19: 7880-7888
The revolutionary changes in hepatitis C treatment: A concise review.
British Columbia Medical Journal. 2019; 61: 72-77
Sofosbuvir and Ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection.
Hepatology. 2020; 71: 31-43
Ledipasvir-sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C.
Hepatology. 2020; 71: 422-430
Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis c virus: part 1 of the DORA Study.
Hepatology. 2020; 71: 456-462
The cost- effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Clin Infect Dis. 2015; 61: 157-168
The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Ann Intern Med. 2012; 156: 263-270
Early treatment of chronic hepatitis C in young children reduces adverse outcomes and is cost effective compared to deferring treatment to adulthood.
J Pediatr. 2020; (XXX:XX-X)
The cost of a QALY.
Q J Med. 2010; 103: 715-720
Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold.
N Engl J Med. 2014 Aug 28; 371: 796-797
Cost effectiveness of early treatment with direct-acting antiviral therapy in adolescent patients with hepatitis C virus infection.
J Pediatr. 2019; 207: 90-96
Hepatitis C virus infection in children and adolescents.
Hepatol Commun. 2017; 1: 87-98
Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?.
Am J Gastroenterol. 2003; 98: 660-663
Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
J Pediatr Gastroenterol Nutr. 2018; 66: 505-515
Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper.
J Pediatr Gastroenterol Nutr. 2020; 71: 407-417
Health-related quality of life in children with hepatitis C acquired in the first year of life.
J Gastroenterol Hepatol. 2008; 23: 226-230
Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.
J Pediatr Gastroenterol Nutr. 2009; 48: 341-347
Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir.
J Pediatr Gastroenterol Nutr. 2018 Jan; 66: 112-116
In Press Accepted Manuscript
N.R-B receives research funding from Gilead. The author declares no conflicts of interest.
© 2020 Published by Elsevier Inc.